Hematological malignancies
Conditions
Brief summary
Primary Objective Part I • To determine the safety and tolerability of Karonudib in escalating doses for the treatment of patients with advanced relapsed/refractory Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) , Diffuse Large B-Cell Lymphoma, Multiple Myeloma (MM) and high-risk Myelodysplastic Syndrome (MDS) Primary Objective Part II To determine the safety and tolerability of Karonudib in combination with other anti-cancer agents for the treatment of patients with advance
Interventions
Sponsors
Oxcia AB, Oxcia AB, Thomas Helledays Stiftelse Foer Medicinsk Forskning
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Objective Part I • To determine the safety and tolerability of Karonudib in escalating doses for the treatment of patients with advanced relapsed/refractory Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) , Diffuse Large B-Cell Lymphoma, Multiple Myeloma (MM) and high-risk Myelodysplastic Syndrome (MDS) Primary Objective Part II To determine the safety and tolerability of Karonudib in combination with other anti-cancer agents for the treatment of patients with advance | — |
Countries
Denmark, Sweden
Outcome results
None listed